CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer

被引：0
|
作者：
Alves, C. [1 ]
Elias, D. [1 ]
Lyng, M. [1 ]
Bak, M. [2 ]
Lykkesfeldt, A. [3 ]
Ditzel, H. [1 ]
机构：
[1] Univ Southern Denmark, Canc & Inflammat Res, Odense, Denmark
[2] Univ Southern Denmark, Pathol, Odense, Denmark
[3] Danish Canc Soc, Res Ctr, Breast Canc Grp Cell Death & Metab, Copenhagen, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61416-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [1] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [2] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
  • [3] Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Scheidemann, Erin R.
    Shajahan-Haq, Ayesha N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [4] High expression of CDK6 confers resistance to fulvestrant in breast cancer cells and is a potential predictor of fulvestrant treatment failure in estrogen receptor-positive breast cancer
    Alves, Carla M. L.
    Elias, Daniel
    Lyng, Maria
    Bak, Martin
    Lykkesfeldt, Anne E.
    Ditzel, Henrik J.
    CANCER RESEARCH, 2015, 75 (22)
  • [5] High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer
    Alves, Carla L.
    Elias, Daniel
    Lyng, Maria
    Bak, Martin
    Kirkegaard, Tove
    Lykkesfeldt, Anne E.
    Ditzel, Henrik J.
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5514 - 5526
  • [6] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [8] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Janice Lu
    Journal of Hematology & Oncology, 8
  • [9] CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
    Zhou, Fiona H.
    Downton, Teesha
    Freelander, Allegra
    Hurwitz, Joshua
    Caldon, C. Elizabeth
    Lim, Elgene
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [10] CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer
    Pesch, Andrea M.
    Hirsh, Nicole
    Chandler, Benjamin C.
    Michmerhuizen, Anna R.
    Ritter, Cassandra L.
    Androsiglio, Marlie
    Wilder-Romans, Kari
    Liu, Meilan
    Gersch, Christina L.
    Larios, Jose M.
    Rae, James M.
    Speers, Corey W.
    CANCER RESEARCH, 2020, 80 (16)
12345